Resveratrol attenuates trimethylamine-N-oxide (TMAO)-induced atherosclerosis by regulating TMAO synthesis and bile acid metabolism via remodeling of the gut microbiota

mBio

Volumn 7, Issue 2, 2016, Pages

  Chen, Ming Liang ^a   Yi, Long ^a   Zhang, Yong ^a   Zhou, Xi ^a   Ran, Li ^a   Yang, Jining ^a   Zhu, Jun Dong ^a   Zhang, Qian Yong ^a   Mi, Man Tian ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; APOLIPOPROTEIN E; BILE ACID; CHOLESTEROL 7ALPHA MONOOXYGENASE; FARNESOID X RECEPTOR; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 15; RESVERATROL; TRIMETHYLAMINE OXIDE; UNCLASSIFIED DRUG; METHYLAMINE; STILBENE DERIVATIVE; TRIMETHYLAMINE; TRIMETHYLOXAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; BIFIDOBACTERIUM; BILE ACID METABOLISM; BILE ACID SYNTHESIS; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; FEMALE; ILEUM; INTESTINE FLORA; LACTOBACILLUS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTECTION; PROTEIN EXPRESSION; ANIMAL; BACTERIUM; C57BL MOUSE; CLASSIFICATION; ENZYMOLOGY; GENETICS; HUMAN; ISOLATION AND PURIFICATION; LIVER; METABOLISM; MICROBIOLOGY;

ANIMALS; ATHEROSCLEROSIS; BACTERIA; BILE ACIDS AND SALTS; CHOLESTEROL 7-ALPHA-HYDROXYLASE; FEMALE; GASTROINTESTINAL MICROBIOME; HUMANS; LIVER; METHYLAMINES; MICE; MICE, INBRED C57BL; STILBENES;

EID: 84965006890     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.02210-15     Document Type: Article

References (49)

1. Murray CJ, Lopez AD. 1997. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 349:1498-1504. http://dx.doi.org/10.1016/S0140-6736(96)07492-2.
2. Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, Feldstein AE, Britt EB, Fu X, Chung YM, Wu Y, Schauer P, Smith JD, Allayee H, Tang WH, DiDonato JA, Lusis AJ, Hazen SL. 2011. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472:57-63. http://dx.doi.org/10.1038/nature09922.
3. Tang WH, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, Wu Y, Hazen SL. 2013. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med 368:1575-1584. http://dx.doi.org/10.1056/NEJMoa1109400.
4. Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, Britt EB, Fu X, Wu Y, Li L, Smith JD, DiDonato JA, Chen J, Li H, Wu GD, Lewis JD, Warrier M, Brown JM, Krauss RM, Tang WH. 2013. Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med 19:576-585. http://dx.doi.org/10.1038/nm.3145.
5. Sayin SI, Wahlström A, Felin J, Jäntti S, Marschall HU, Bamberg K, Angelin B, Hyötyläinen T, Orešič M, Bäckhed F. 2013. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-betamuricholic acid, a naturally occurring FXR antagonist. Cell Metab 17: 225-235. http://dx.doi.org/10.1016/j.cmet.2013.01.003.
6. Jones ML, Tomaro-Duchesneau C, Prakash S. 2014. The gut microbiome, probiotics, bile acids axis, and human health. Trends Microbiol 22:306-308. http://dx.doi.org/10.1016/j.tim.2014.04.010.
7. Li-Hawkins J, Gåfvels M, Olin M, Lund EG, Andersson U, Schuster G, Björkhem I, Russell DW, Eggertsen G. 2002. Cholic acid mediates negative feedback regulation of bile acid synthesis in mice. J Clin Invest 110: 1191-1200. http://dx.doi.org/10.1172/JCI16309.
8. Hylemon PB, Zhou H, Pandak WM, Ren S, Gil G, Dent P. 2009. Bile acids as regulatory molecules. J Lipid Res 50:1509-1520. http://dx.doi.org/10.1194/jlr.R900007-JLR200.
9. Miyata M, Takamatsu Y, Kuribayashi H, Yamazoe Y. 2009. Administration of ampicillin elevates hepatic primary bile Acid synthesis through suppression of ileal fibroblast growth factor 15 expression. J Pharmacol Exp Ther 331:1079-1085. http://dx.doi.org/10.1124/jpet.109.160093.
10. Degirolamo C, Rainaldi S, Bovenga F, Murzilli S, Moschetta A. 2014. Microbiota modification with probiotics induces hepatic bile acid synthesis via downregulation of the FXR-FGF15 axis in mice. Cell Rep 7:12-18. http://dx.doi.org/10.1016/j.celrep.2014.02.032.
11. Miyata M, Sakaida Y, Matsuzawa H, Yoshinari K, Yamazoe Y. 2011. Fibroblast growth factor 19 treatment ameliorates disruption of hepatic lipid metabolism in farnesoid X receptor (FXR)-null mice. Biol Pharm Bull 34:1885-1889. http://dx.doi.org/10.1248/bpb.34.1885.
12. Li F, Jiang CT, Krausz KW, Li YF, Albert I, Hao HP, Fabre KM, Mitchell JB, Patterson AD, Gonzalez FJ. 2013. Microbiome remodelling leads to inhibition of intestinal farnesoid X receptor signalling and decreased obesity. Nat Commun 4:2384. http://dx.doi.org/10.1038/ncomms3384.
13. Chung JH, Manganiello V, Dyck JR. 2012. Resveratrol as a calorie restriction mimetic: therapeutic implications. Trends Cell Biol 22:546-554. http://dx.doi.org/10.1016/j.tcb.2012.07.004.
14. Subramanian L, Youssef S, Bhattacharya S, Kenealey J, Polans AS, van Ginkel PR. 2010. Resveratrol: challenges in translation to the clinic—a critical discussion. Clin Cancer Res 16:5942-5948. http://dx.doi.org/10.1158/1078-0432.CCR-10-1486.
15. Asensi M, Medina I, Ortega A, Carretero J, Baño MC, Obrador E, Estrela JM. 2002. Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radic Biol Med 33:387-398. http://dx.doi.org/10.1016/S0891-5849(02)00911-5.
16. Shin NR, Lee JC, Lee HY, Kim MS, Whon TW, Lee MS, Bae JW. 2014. An increase in the Akkermansia spp. population induced by metformin treatment improves glucose homeostasis in diet-induced obese mice. Gut 63:727-735. http://dx.doi.org/10.1136/gutjnl-2012-303839.
17. Anhê FF, Roy D, Pilon G, Dudonné S, Matamoros S, Varin TV, Garofalo C, Moine Q, Desjardins Y, Levy E, Marette A. 2015. A polyphenol-rich cranberry extract protects from diet-induced obesity, insulin resistance and intestinal inflammation in association with increased Akkermansia spp. population in the gut microbiota of mice. Gut 64: 872-883 http://dx.doi.org/10.1136/gutjnl-2014-307142.
18. Larrosa M, Yañéz-Gascón MJ, Selma MV, González-Sarrías A, Toti S, Cerón JJ, Tomás-Barberán F, Dolara P, Espín JC. 2009. Effect of a low dose of dietary resveratrol on colon microbiota, inflammation and tissue damage in a DSS-induced colitis rat model. J Agric Food Chem 57: 2211-2220. http://dx.doi.org/10.1021/jf803638d.
19. Jung CM, Heinze TM, Schnackenberg LK, Mullis LB, Elkins SA, Elkins CA, Steele RS, Sutherland JB. 2009. Interaction of dietary resveratrol with animal-associated bacteria. FEMS Microbiol Lett 297:266-273. http://dx.doi.org/10.1111/j.1574-6968.2009.01691.x.
20. Queipo-Ortuño MI, Boto-Ordóñez M, Murri M, Gomez-Zumaquero JM, Clemente-Postigo M, Estruch R, Cardona Diaz F, Andrés-Lacueva C, Tinahones FJ. 2012. Influence of red wine polyphenols and ethanol on the gut microbiota ecology and biochemical biomarkers. Am J Clin Nutr 95:1323-1334. http://dx.doi.org/10.3945/ajcn.111.027847.
21. Qiao Y, Sun J, Xia S, Tang X, Shi Y, Le G. 2014. Effects of resveratrol on gut microbiota and fat storage in a mouse model with high-fat-induced obesity. Food Funct 5:1241-1249. http://dx.doi.org/10.1039/c3fo60630a.
22. Etxeberria U, Arias N, Boqué N, Macarulla MT, Portillo MP, Martínez JA, Milagro FI. 2015. Reshaping faecal gut microbiota composition by the intake of trans-resveratrol and quercetin in high-fat sucrose diet-fed rats. J Nutr Biochem 26:651-660. http://dx.doi.org/10.1016/j.jnutbio.2015.01.002.
23. Bennett BJ, de Aguiar Vallim TQ, Wang Z, Shih DM, Meng Y, Gregory J, Allayee H, Lee R, Graham M, Crooke R, Edwards PA, Hazen SL, Lusis AJ. 2013. Trimethylamine-N-oxide, a metabolite associated with atherosclerosis, exhibits complex genetic and dietary regulation. Cell Metab 17: 49-60. http://dx.doi.org/10.1016/j.cmet.2012.12.011.
24. Ridlon JM, Kang DJ, Hylemon PB. 2006. Bile salt biotransformations by human intestinal bacteria. J Lipid Res 47:241-259. http://dx.doi.org/10.1194/jlr.R500013-JLR200.
25. Zhang Y, Limaye PB, Lehman-McKeeman LD, Klaassen CD. 2012. Dysfunction of organic anion transporting polypeptide 1a1 alters intestinal bacteria and bile acid metabolism in mice. PLoS One 7:e34522. http://dx.doi.org/10.1371/journal.pone.0034522.
26. Alrefai WA, Gill RK. 2007. Bile acid transporters: structure, function, regulation and pathophysiological implications. Pharm Res 24: 1803-1823. http://dx.doi.org/10.1007/s11095-007-9289-1.
27. Herrema H, Meissner M, van Dijk TH, Brufau G, Boverhof R, Oosterveer MH, Reijngoud DJ, Müller M, Stellaard F, Groen AK, Kuipers F. 2010. Bile salt sequestration induces hepatic de novo lipogenesis through farnesoid X receptor- and liver X receptor alpha-controlled metabolic pathways in mice. Hepatology 51:806-816. http://dx.doi.org/10.1002/hep.23408.
28. Out C, Hageman J, Bloks VW, Gerrits H, Sollewijn Gelpke MD, Bos T, Havinga R, Smit MJ, Kuipers F, Groen AK. 2011. Liver receptor homolog-1 is critical for adequate up-regulation of Cyp7a1 gene transcription and bile salt synthesis during bile salt sequestration. Hepatology 53:2075-2085. http://dx.doi.org/10.1002/hep.24286.
29. Chiang JY. 2009. Bile acids: regulation of synthesis. J Lipid Res 50: 1955-1966. http://dx.doi.org/10.1194/jlr.R900010-JLR200.
30. Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, Gonzalez FJ. 2000. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 102:731-744. http://dx.doi.org/10.1016/S0092-8674(00)00062-3.
31. Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, McDonald JG, Luo G, Jones SA, Goodwin B, Richardson JA, Gerard RD, Repa JJ, Mangelsdorf DJ, Kliewer SA. 2005. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2:217-225. http://dx.doi.org/10.1016/j.cmet.2005.09.001.
32. Lu TT, Makishima M, Repa JJ, Schoonjans K, Kerr TA, Auwerx J, Mangelsdorf DJ. 2000. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol Cell 6:507-515. http://dx.doi.org/10.1016/S1097-2765(00)00050-2.
33. Xiao D, Singh SV. 2008. z-Guggulsterone, a constituent of ayurvedic medicinal plant Commiphora mukul, inhibits angiogenesis in vitro and in vivo. Mol Cancer Ther 7:171-180. http://dx.doi.org/10.1158/1535-7163.MCT-07-0491.
34. Kemper JK, Xiao Z, Ponugoti B, Miao J, Fang S, Kanamaluru D, Tsang S, Wu SY, Chiang CM, Veenstra TD. 2009. FXR acetylation is normally dynamically regulated by p300 and SIRT1 but constitutively elevated in metabolic disease states. Cell Metab 10:392-404. http://dx.doi.org/10.1016/j.cmet.2009.09.009.
35. Purushotham A, Xu Q, Lu J, Foley JF, Yan X, Kim DH, Kemper JK, Li X. 2012. Hepatic deletion of SIRT1 decreases hepatocyte nuclear factor 1 alpha/farnesoid X receptor signaling and induces formation of cholesterol gallstones in mice. Mol Cell Biol 32:1226-1236. http://dx.doi.org/10.1128/MCB.05988-11.
36. Kulkarni SS, Cantó C. 2015. The molecular targets of resveratrol. Biochim Biophys Acta 1852:1114-1123. http://dx.doi.org/10.1016/j.bbadis.2014.10.005.
37. El-Mowafy AM, El-Mesery ME, Salem HA, Al-Gayyar MM, Darweish MM. 2010. Prominent chemopreventive and chemoenhancing effects for resveratrol: unraveling molecular targets and the role of C-reactive protein. Chemotherapy 56:60-65. http://dx.doi.org/10.1159/000298821.
38. Zhang Y, Chen ML, Zhou Y, Yi L, Gao YX, Ran L, Chen SH, Zhang T, Zhou X, Zou D, Wu B, Wu Y, Chang H, Zhu JD, Zhang QY, Mi MT. 2015. Resveratrol improves hepatic steatosis by inducing autophagy through the cAMP signaling pathway. Mol Nutr Food Res 59:1443-1457. http://dx.doi.org/10.1002/mnfr.201500016.
39. Wang Z, Roberts AB, Buffa JA, Levison BS, Zhu W, Org E, Gu X, Huang Y, Zamanian-Daryoush M, Culley MK, DiDonato AJ, Fu X, Hazen JE, Krajcik D, DiDonato JA, Lusis AJ, Hazen SL. 2015. Nonlethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis. Cell 163:1585-1595. http://dx.doi.org/10.1016/j.cell.2015.11.055.
40. Swann JR, Want EJ, Geier FM, Spagou K, Wilson ID, Sidaway JE, Nicholson JK, Holmes E. 2011. Systemic gut microbial modulation of bile acid metabolism in host tissue compartments. Proc Natl Acad Sci U S A 108:4523-4530. http://dx.doi.org/10.1073/pnas.1006734107.
41. Begley M, Hill C, Gahan CGM. 2006. Bile salt hydrolase activity in probiotics. Appl Environ Microbiol 72:1729-1738. http://dx.doi.org/10.1128/AEM.72.3.1729-1738.2006.
42. Joyce SA, MacSharry J, Casey PG, Kinsella M, Murphy EF, Shanahan F, Hill C, Gahan CG. 2014. Regulation of host weight gain and lipid metabolism by bacterial bile acid modification in the gut. Proc Natl Acad Sci U S A 111:7421-7426. http://dx.doi.org/10.1073/pnas.1323599111.
43. Chen Q, Wang E, Ma L, Zhai P. 2012. Dietary resveratrol increases the expression of hepatic 7alpha-hydroxylase and ameliorates hypercholesterolemia in high-fat fed C57BL/6J mice. Lipids Health Dis 11:56. http://dx.doi.org/10.1186/1476-511X-11-56.
44. Chothe PP, Swaan PW. 2014. Resveratrol promotes degradation of the human bile acid transporter ASBT (SLC10A2). Biochem J 459:301-312. http://dx.doi.org/10.1042/BJ20131428.
45. De Aguiar Vallim TQ, Tarling EJ, Edwards PA. 2013. Pleiotropic roles of bile acids in metabolism. Cell Metab 17:657-669. http://dx.doi.org/10.1016/j.cmet.2013.03.013.
46. Sayin SI, Wahlström A, Felin J, Jäntti S, Marschall HU, Bamberg K, Angelin B, Hyötyläinen T, Orešič M, Bäckhed F. 2013. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-betamuricholic acid, a naturally occurring FXR antagonist. Cell Metab 17: 225-235. http://dx.doi.org/10.1016/j.cmet.2013.01.003.
47. Liberles SD, Buck LB. 2006. A second class of chemosensory receptors in the olfactory epithelium. Nature 442:645-650. http://dx.doi.org/10.1038/nature05066.
48. Bai C, Biwersi J, Verkman AS, Matthay MA. 1998. A mouse model to test the in vivo efficacy of chemical chaperones. J Pharmacol Toxicol Methods 40:39-45. http://dx.doi.org/10.1016/S1056-8719(98)00034-3.
49. Mello CC, Barrick D. 2003. Measuring the stability of partly folded proteins using TMAO. Protein Sci 12:1522-1529. http://dx.doi.org/10.1110/ps.0372903.